BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 29954071)

  • 21. MCPIP1 Exogenous Overexpression Inhibits Pathways Regulating MYCN Oncoprotein Stability in Neuroblastoma.
    Boratyn E; Nowak I; Durbas M; Horwacik I; Sawicka A; Rokita H
    J Cell Biochem; 2017 Jul; 118(7):1741-1755. PubMed ID: 27935099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wnt signalling is a bi-directional vulnerability of cancer cells.
    Duffy DJ; Krstic A; Schwarzl T; Halasz M; Iljin K; Fey D; Haley B; Whilde J; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
    Oncotarget; 2016 Sep; 7(37):60310-60331. PubMed ID: 27531891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
    Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
    Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
    Li N; Fu H; Hewitt SM; Dimitrov DS; Ho M
    Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6623-E6631. PubMed ID: 28739923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma.
    He XY; Tan ZL; Mou Q; Liu FJ; Liu S; Yu CW; Zhu J; Lv LY; Zhang J; Wang S; Bao LM; Peng B; Zhao H; Zou L
    Clin Cancer Res; 2017 Jun; 23(11):2905-2918. PubMed ID: 28003306
    [No Abstract]   [Full Text] [Related]  

  • 26. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
    Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells.
    Rellinger EJ; Craig BT; Alvarez AL; Dusek HL; Kim KW; Qiao J; Chung DH
    Surgery; 2017 Mar; 161(3):747-752. PubMed ID: 27919448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma.
    Alborzinia H; Chen Z; Yildiz U; Freitas FP; Vogel FCE; Varga JP; Batani J; Bartenhagen C; Schmitz W; Büchel G; Michalke B; Zheng J; Meierjohann S; Girardi E; Espinet E; Flórez AF; Dos Santos AF; Aroua N; Cheytan T; Haenlin J; Schlicker L; Xavier da Silva TN; Przybylla A; Zeisberger P; Superti-Furga G; Eilers M; Conrad M; Fabiano M; Schweizer U; Fischer M; Schulze A; Trumpp A; Friedmann Angeli JP
    EMBO Mol Med; 2023 Aug; 15(8):e18014. PubMed ID: 37435859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
    Colicchia V; Petroni M; Guarguaglini G; Sardina F; Sahún-Roncero M; Carbonari M; Ricci B; Heil C; Capalbo C; Belardinilli F; Coppa A; Peruzzi G; Screpanti I; Lavia P; Gulino A; Giannini G
    Oncogene; 2017 Aug; 36(33):4682-4691. PubMed ID: 28394338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-induced cytotoxic effects in neuroblastoma.
    Marengo B; De Ciucis C; Verzola D; Pistoia V; Raffaghello L; Patriarca S; Balbis E; Traverso N; Cottalasso D; Pronzato MA; Marinari UM; Domenicotti C
    Free Radic Biol Med; 2008 Feb; 44(3):474-82. PubMed ID: 17991446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma.
    Borankova K; Krchniakova M; Leck LYW; Kubistova A; Neradil J; Jansson PJ; Hogarty MD; Skoda J
    Cell Death Dis; 2023 Nov; 14(11):747. PubMed ID: 37973789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
    Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
    Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of N‑Myc inhibits neuroblastoma cell growth via the Wnt/β‑catenin signaling pathway.
    Wang Y; Gao S; Wang W; Xia Y; Liang J
    Mol Med Rep; 2018 Jul; 18(1):377-384. PubMed ID: 29749516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.
    Woo CW; Tan F; Cassano H; Lee J; Lee KC; Thiele CJ
    Pediatr Blood Cancer; 2008 Feb; 50(2):208-12. PubMed ID: 17420990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform.
    Wu D; Berg J; Arlt B; Röhrs V; Al-Zeer MA; Deubzer HE; Kurreck J
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.